Nurix Therapeutics, Inc. reported $702M of revenue over the trailing twelve months, +739% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $702M (to Q3 2026). Net income: $295M, trailing twelve months to Q3 2026. Free cash flow: $370M, trailing twelve months to Q3 2026. Operating margin: −763%, trailing twelve months to Q3 2026.

NRIXNurix Therapeutics, Inc.

Healthcare

$25.33+152% 1Y

$25.33

$9.8452 weeks$27.79

NRIX as reported

Nurix Therapeutics, Inc. reported $702M of revenue over the trailing twelve months, +739% on the year before. 8 reported series are charted on this page, each one as filed.

$702M

Revenue, trailing twelve months · to Q3 2026 · +739% against the twelve months before

Net income: $295M
Net income · −220% year on year · trailing twelve months to Q3 2026
Free cash flow: $370M
Free cash flow · −253% year on year · trailing twelve months to Q3 2026
Operating margin: −763%
Operating margin · trailing twelve months to Q3 2026

Details›

Every series Ryufin has for NRIX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$702M	+739%	Q3 2026
Net income	$295M	−220%	Q3 2026
EPS	$2.30	−177%	Q3 2026
Operating margin	−763%	n/a	Q3 2026
Net margin	−720%	n/a	Q3 2026
ROE	−41%	n/a	Q3 2026
ROA	−31%	n/a	Q3 2026
Free cash flow	$370M	−253%	Q3 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.